Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04466215 · ClinicalTrials.gov registry record · Phase 2
Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo
A Phase 2 study of Alcohol Use Disorder, sponsored by The Scripps Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04466215 is a Phase 2 study of Alcohol Use Disorder that has completed, run by The Scripps Research Institute. The registered enrollment target is 50 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04466215, a Phase 2 study of Alcohol Use Disorder, has completed, sponsored by The Scripps Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The hypotheses under test are that subjects with alcohol use disorder (AUD) of moderate or greater severity treated with CORT118335 will report decreased craving for alcohol following alcohol exposure in the laboratory and report significantly less drinking under naturalistic conditions, than those treated with placebo.
Conditions Studied
Interventions
- DRUG Placebo oral tablet
- DRUG Miricorilant
Study Locations (1)
California
- The Scripps Research Institute Pearson Center for Alcoholism and Addiction Research - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-04-15 |
| Est. Completion | 2022-06-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04466215
The ClinicalTrials.gov registry entry for NCT04466215 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (85% lower). The listed sponsor is The Scripps Research Institute, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04466215 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04466215 about?
NCT04466215 is a clinical study titled "Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo". The hypotheses under test are that subjects with alcohol use disorder (AUD) of moderate or greater severity treated with CORT118335 will report decreased craving for alcohol following alcohol exposure in the laboratory and report significantly less drinking under naturalistic conditions, than those ...
What is the current status of trial NCT04466215?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2021-04-15. Estimated completion is 2022-06-07.
What conditions does trial NCT04466215 study?
This clinical trial studies the following conditions: Alcohol Use Disorder.
What interventions are being tested in trial NCT04466215?
The interventions under investigation include: Placebo oral tablet (DRUG), Miricorilant (DRUG).
Who is sponsoring clinical trial NCT04466215?
This trial is sponsored by The Scripps Research Institute, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04466215 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
RECRUITING · Phase 2
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial
RECRUITING · Phase 2
-
Cannabis' Impact on Alcohol Consumption
RECRUITING · Phase 2
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Semaglutide Therapy for Alcohol Reduction (STAR)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.